Jason Rickard - Feb 28, 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
SVP, Chief Operating Officer
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Feb 28, 2022
Transactions value $
-$311,921
Form type
4
Date filed
3/2/2022, 03:00 PM
Previous filing
Jan 21, 2022
Next filing
Mar 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale -$20.6K -1.91K -0.54% $10.77 354K Feb 28, 2022 Direct F1
transaction IRWD Class A Common Stock Sale -$33.9K -3.15K -0.89% $10.77 351K Feb 28, 2022 Direct F2
transaction IRWD Class A Common Stock Sale -$64.9K -6.02K -1.72% $10.77 345K Feb 28, 2022 Direct F3
transaction IRWD Class A Common Stock Sale -$119K -11.1K -3.21% $10.77 334K Feb 28, 2022 Direct F4
transaction IRWD Class A Common Stock Sale -$73.5K -6.82K -2.04% $10.77 327K Feb 28, 2022 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
F4 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
F5 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.